Will be discontinued from commercial sale worldwide in July 2018. This withdrawal is on commercial grounds only and not related to safety or efficacy of the medicine. Albiglutide is not on the formulary, but may be encountered when treating out-of-area patients.
Alogliptin / metformin (Vipdomet®)
Alogliptin / pioglitazone (Incresync®)
Canagliflozin / metformin IR (Vokanamet®)
Dapagliflozin / metformin (Xigduo®)
Empagliflozin + linagliptin (Glyxambi®)
Empagliflozin and Metformin (Synjardy®)
Linagliptin/ metformin (Jentadueto®)
Lixisenatide (Lyxumia▼®) (injection)
Once daily injection for type 2 diabetes
Saxagliptin and metformin (Komboglyze®)
Sitagliptin and Metformin (Janumet®)
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
High Cost Medicine
Cancer Drugs Fund
Traffic Light Status Information
Primary and Secondary Care (unrestricted) – may be prescribed by GPs, hospital doctors or other qualified prescribers in primary and secondary care
Amber Initiated: first prescription from specialist, on going supplies from primary care (or when stabilised on therapy).
Amber recommended: first prescription may be supplied by primary care under the advice of a specialist.
For initiation within a specialist service followed by ongoing prescribing in primary care according to published shared care guidance
For initiation and ongoing prescribing in secondary care only. Medicines in this category may be further restricted to use by specific hospital departments only.